The narrative surrounding Autolus Therapeutics is shifting due to recalibrated targets and fair value assessments. Analyst outlooks and recent approvals, including those for AUCATZYL, may be redefining the company's long-term story and valuation. However, some reports appear to confuse Autolus Therapeutics with the Auto Trader Group, introducing uncertainty into the narrative.